Physician profile
Brooke Storer
NPI 1043506751
$3,477.78
in general payments reported to CMS, 2019-2025
31 companies · $901 in 2025
The $901 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $76.18 · 2021: $346 · 2022: $349 · 2023: $806 · 2024: $644 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.92 |
| Education | $109.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $478.30 | 2021-2025 | |
| Abbvie INC. | $434.99 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Astellas Pharma US INC | $375.25 | 2019-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $214.32 | 2020-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $209.09 | 2024-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $188.29 | 2019-2025 | |
| Minerva Surgical, INC | $188.08 | 2023-2025 | |
| Amgen INC. | $180.57 | 2019-2024 | Prolia, Evenity |
| Organon LLC | $165.21 | 2024-2025 | Nexplanon |
| Pfizer INC. | $148.69 | 2021-2025 | |
| Avion Pharmaceuticals | $125.92 | 2019-2023 | Balcoltra |
| Millicent US INC | $122.00 | 2023-2025 | Intrarosa, Femlyv, Femring |
| Medtronic, INC. | $83.76 | 2022-2025 | Truclear, Ligasure |
| Agile Therapeutics, INC. | $72.68 | 2021-2024 | Twirla |
| Meditrina | $62.72 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $53.18 | 2024-2025 | Zurzuvae |
| Dexcom, INC. | $51.04 | 2025 | Dexcom G6 Transmitter |
| Gynesonics, INC. | $43.43 | 2021 | |
| Therapeuticsmd, INC. | $39.48 | 2019-2021 | |
| Exeltis, USA INC. | $38.73 | 2021-2022 | |
| Coopersurgical, INC. | $28.91 | 2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $25.47 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $21.31 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $21.26 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.64 | 2021 | |
| Avanos Medical | $17.95 | 2019 | |
| Evofem Biosciences, INC. | $14.41 | 2021 | |
| Solventum Corporation | $14.31 | 2024 | V.A.C.Ulta, Prevena |
| Intra-Sana Laboratories | $13.77 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Radius Health, INC. | $12.36 | 2021 | |
| Intuitive Surgical, INC. | $11.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Storer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.